Dexrazoxane administration from cycle 1 versus cycle 4 in patients with soft tissue sarcoma resulted in similar median overall survival (19.6 vs 14.8 months; p=0.24) and low overall cardiotoxicity.
Cohort (n=106)
Yes
Does the use of dexrazoxane alongside doxorubicin and olaratumab result in low cardiotoxicity and preserve overall survival in patients with soft tissue sarcoma?
In patients with soft tissue sarcoma treated with doxorubicin and olaratumab, the use of dexrazoxane was associated with a low (7%) incidence of cardiotoxicity without compromising overall survival.
Absolute Event Rate: 19.6% vs 14.8%
p-value: p=0.24
BACKGROUND AND PURPOSE: Anthracycline-associated cardiotoxicity is a challenge that dexrazoxane may reduce. The aim of this study was to report the overall survival (OS), incidence of cardiotoxicity and dexrazoxane use in a Danish population-based cohort of patients with soft tissue sarcoma (STS) treated with doxorubicin, olaratumab and dexrazoxane. PATIENTS/MATERIAL AND METHODS: We performed a retrospective study of adults (≥18 years) with locally advanced or metastatic STS treated with doxorubicin, olaratumab and dexrazoxane between 2015 and 2019 at Herlev University Hospital (Herlev) and Aarhus University Hospital (Aarhus). Dexrazoxane was administered from cycle 1 at Herlev and from cycle 4 at Aarhus. OS was measured from doxorubicin initiation to death. Cardiotoxicity was defined as a >10 percentage‑point decline in left ventricular ejection fraction to <50% compared with baseline. RESULTS: In total, 106 patients were included: 71 patients (67%) from Herlev and 35 (33%) from Aarhus. Mean age was 59 years, 59% were female. Median OS was 18 months (95% confidence interval CI: 11.0-20.7) and median cumulative doxorubicin dose was 320.7 mg/m² (range: 37.5-605.4). Dexrazoxane was administered to 68 patients (96%) at Herlev and 18 (51%) at Aarhus. Seven patients (7%) developed cardiotoxicity (Herlev n = 4; Aarhus n = 3). Median OS was 19.6 months at Herlev and 14.8 months at Aarhus (p = 0.24). Neutropenic fever occurred in 27 patients (38%) at Herlev and six patients (17%) at Aarhus (p = 0.88). INTERPRETATION: Doxorubicin with olaratumab and dexrazoxane resulted in a low incidence of cardiotoxicity and OS was consistent with previously reported.
Vitfell-Rasmussen et al. (Tue,) conducted a cohort in Soft tissue sarcoma (n=106). Dexrazoxane administration from cycle 1 vs. Dexrazoxane administration from cycle 4 was evaluated on Median overall survival (months) (p=0.24). Dexrazoxane administration from cycle 1 versus cycle 4 in patients with soft tissue sarcoma resulted in similar median overall survival (19.6 vs 14.8 months; p=0.24) and low overall cardiotoxicity.